Tillkännagivande • Jul 13
Cresco Labs Inc. to Report Q2, 2026 Results on Aug 06, 2026 Cresco Labs Inc. announced that they will report Q2, 2026 results Pre-Market on Aug 06, 2026 Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Director Michele Roberts was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Apr 23
Cresco Labs Inc. to Report Q1, 2026 Results on May 08, 2026 Cresco Labs Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026 Tillkännagivande • Feb 23
Cresco Labs Inc. to Report Q4, 2025 Results on Mar 05, 2026 Cresco Labs Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Mar 05, 2026 Tillkännagivande • Jan 30
Cresco Labs Inc. has filed a Follow-on Equity Offering in the amount of CAD 140 million. Cresco Labs Inc. has filed a Follow-on Equity Offering in the amount of CAD 140 million.
Security Name: Subordinate Voting Shares
Security Type: Common Stock
Transaction Features: At the Market Offering Tillkännagivande • Nov 06
Cresco Labs Inc. Reports Unaudited Impairment Loss for the Third Quarter Ended September 30, 2025 Cresco Labs Inc. reported unaudited impairment loss for the third quarter ended September 30, 2025. For the period, the company reported impairment loss of $2,365,000 against $2,320,000 a year ago. non-cash impairment charges of $2 million related to California assets being considered held for sale. Tillkännagivande • Oct 22
Cresco Labs Inc. to Report Q3, 2025 Results on Nov 05, 2025 Cresco Labs Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 05, 2025 Tillkännagivande • Jul 22
Cresco Labs Inc., Annual General Meeting, Sep 16, 2025 Cresco Labs Inc., Annual General Meeting, Sep 16, 2025. Tillkännagivande • Jul 17
Cresco Labs Inc. to Report Q2, 2025 Results on Aug 07, 2025 Cresco Labs Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 07, 2025 Tillkännagivande • May 29
Cresco Labs Inc. to Report Q1, 2025 Results on May 30, 2025 Cresco Labs Inc. announced that they will report Q1, 2025 results on May 30, 2025 Tillkännagivande • Apr 29
Cresco Labs Inc. to Report Q1, 2025 Results on May 09, 2025 Cresco Labs Inc. announced that they will report Q1, 2025 results Pre-Market on May 09, 2025 Tillkännagivande • Mar 03
Cresco Labs Inc. to Report Q4, 2024 Results on Mar 12, 2025 Cresco Labs Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 12, 2025 Board Change • Dec 30
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Michele Roberts was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Nov 12
No longer forecast to breakeven The 8 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$14.8m in 2025. New consensus forecast suggests the company will make a loss of US$13.4m in 2025. Reported Earnings • Nov 10
Third quarter 2024 earnings released: US$0.03 loss per share (vs US$0.34 loss in 3Q 2023) Third quarter 2024 results: US$0.03 loss per share (improved from US$0.34 loss in 3Q 2023). Revenue: US$179.8m (down 3.8% from 3Q 2023). Net loss: US$10.5m (loss narrowed 91% from 3Q 2023). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Tillkännagivande • Oct 17
Cresco Labs Inc. to Report Q3, 2024 Results on Nov 08, 2024 Cresco Labs Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 08, 2024 Tillkännagivande • Sep 29
Cresco Labs Inc. Announces Resignation of Tarik Brooks as Board of Directors Cresco Labs Inc. announced that Tarik Brooks has resigned from the Company's Board of Directors to devote his time to other interests. Tillkännagivande • Sep 12
Cresco Labs Inc. Announces CFO Changes Cresco Labs Inc. announced that Dennis Olis, Chief Financial Officer, will retire from Cresco Labs after a planned transition to Sharon Schuler, an experienced financial and strategy executive. Schuler recently joined Cresco Labs while preparing to take the role of Chief Financial Officer upon Olis's departure. Schuler brings an extensive corporate finance background in publicly traded wholesalers and retailers, most recently as an executive leadership team member at BJ's Wholesale Club, a membership warehouse club spanning 244 clubs and 178 gas stations, across 20 states with $20 billion in annual revenue. Olis has served as Cresco Labs CFO since July 2020. During his tenure, Cresco Labs grew from $125 million in annual revenue to more than $735 million1 today. The Company also saw significant profitability improvements with Adjusted EBITDA margin improving by 2,900 basis points and annual operating cashflow improving by over $100 million annually 2. He successfully prepared the Company for future U.S. listings through conversion to US GAAP and SOX compliance readiness. For the last three years, Schuler was responsible for planning and analysis of BJ's Wholesale Club's short and long-term financial outlook. Prior to that, she spent over 20 years in senior financial management roles for large public and private national retailers including The TJX Companies, Clarks America, and Caleres. Schuler holds an MBA in Integrated Management and a bachelor's in economics from Michigan State University. New Risk • Sep 11
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$172m Forecast net loss in 1 year: US$29m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$29m net loss next year). Significant insider selling over the past 3 months (€373k sold). Breakeven Date Change • Sep 11
No longer forecast to breakeven The 9 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$14.8m in 2025. New consensus forecast suggests the company will make a loss of US$846.2k in 2025. New Risk • Aug 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Significant insider selling over the past 3 months (€513k sold). Reported Earnings • Aug 09
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.12 loss in 2Q 2023) Second quarter 2024 results: US$0.16 loss per share (further deteriorated from US$0.12 loss in 2Q 2023). Revenue: US$184.4m (down 4.8% from 2Q 2023). Net loss: US$54.3m (loss widened 49% from 2Q 2023). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Tillkännagivande • Jul 23
Cresco Labs Inc. to Report Q2, 2024 Results on Aug 08, 2024 Cresco Labs Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 08, 2024 Recent Insider Transactions • Jun 18
Co-Founder & Independent Director recently sold €160k worth of stock On the 14th of June, Robert Sampson sold around 100k shares on-market at roughly €1.60 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €246k. Robert has been a net seller over the last 12 months, reducing personal holdings by €891k. New Risk • Jun 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (6.0% increase in shares outstanding). Significant insider selling over the past 3 months (€330k sold). New Risk • Jun 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (4.9% increase in shares outstanding). Significant insider selling over the past 3 months (€330k sold). Recent Insider Transactions • Jun 09
Co-Founder & Independent Director recently sold €84k worth of stock On the 31st of May, Robert Sampson sold around 50k shares on-market at roughly €1.68 per share. This transaction amounted to 8.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €246k. Robert has been a net seller over the last 12 months, reducing personal holdings by €707k. Recent Insider Transactions • May 29
Co-Founder & Independent Director recently sold €246k worth of stock On the 24th of May, Robert Sampson sold around 131k shares on-market at roughly €1.88 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Robert has been a net seller over the last 12 months, reducing personal holdings by €623k. Reported Earnings • May 19
First quarter 2024 earnings released: US$0.015 loss per share (vs US$0.085 loss in 1Q 2023) First quarter 2024 results: US$0.015 loss per share (improved from US$0.085 loss in 1Q 2023). Revenue: US$184.3m (down 3.3% from 1Q 2023). Net loss: US$5.19m (loss narrowed 80% from 1Q 2023). Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Tillkännagivande • May 17
Cresco Labs Inc. (CNSX:CL) acquired Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC for $9.8 million. Cresco Labs Inc. (CNSX:CL) acquired Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC for $9.8 million on April 24, 2024. Consideration consists of a mix of initial cash consideration, deferred consideration and equity. As part of the acquisition, the Cresco Labs Inc. acquired two operating dispensaries in Pennsylvania, as well as the rights to open a new store under a third license in the future. Cresco Labs Inc. (CNSX:CL) completed the acquisition of Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC on April 24, 2024. Tillkännagivande • May 01
Cresco Labs Inc. to Report Q1, 2024 Results on May 15, 2024 Cresco Labs Inc. announced that they will report Q1, 2024 results Pre-Market on May 15, 2024 Tillkännagivande • Apr 11
Cresco Labs Inc., Annual General Meeting, Jun 10, 2024 Cresco Labs Inc., Annual General Meeting, Jun 10, 2024. Breakeven Date Change • Apr 10
Forecast to breakeven in 2026 The 13 analysts covering Cresco Labs expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 53% per year to 2025. The company is expected to make a profit of US$97.2m in 2026. Average annual earnings growth of 97% is required to achieve expected profit on schedule. New Risk • Mar 15
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$180m Forecast net loss in 2 years: US$22m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$22m net loss in 2 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Reported Earnings • Mar 14
Full year 2023 earnings released: US$0.53 loss per share (vs US$0.71 loss in FY 2022) Full year 2023 results: US$0.53 loss per share (improved from US$0.71 loss in FY 2022). Revenue: US$770.9m (down 6.6% from FY 2022). Net loss: US$179.9m (loss narrowed 15% from FY 2022). Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. Breakeven Date Change • Mar 14
Forecast to breakeven in 2025 The 8 analysts covering Cresco Labs expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 85% to 2024. The company is expected to make a profit of US$21.3m in 2025. Average annual earnings growth of 171% is required to achieve expected profit on schedule. New Risk • Mar 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Significant insider selling over the past 3 months (€377k sold). Tillkännagivande • Feb 28
Cresco Labs Inc. to Report Q4, 2023 Results on Mar 13, 2024 Cresco Labs Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 13, 2024 Tillkännagivande • Feb 01
Cresco Labs Inc. Promotes Greg Butler to the Position of President Cresco Labs Inc. announce the promotion of Greg Butler to the position of President. In this role, Butler will oversee all aspects of Cresco Labs' operations, including production, retail operations, marketing and sales, corporate planning, and investor relations. Butler joined Cresco Labs in 2020 as Chief Commercial Officer and has advised the company since 2018. He has been instrumental in innovating and professionalizing all aspects of Cresco Labs' business including strategic planning, wholesale operations, and retail expansion. Prior to Cresco Labs, Butler had over two decades of experience leading large iconic and insurgent brands for both large Fortune 500 and smaller privately owned businesses. New Risk • Jan 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). Shareholders have been diluted in the past year (7.7% increase in shares outstanding). Significant insider selling over the past 3 months (€377k sold). New Risk • Dec 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$44m net loss in 3 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding). Reported Earnings • Nov 17
Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.033 loss in 3Q 2022) Third quarter 2023 results: US$0.34 loss per share (further deteriorated from US$0.033 loss in 3Q 2022). Revenue: US$190.6m (down 7.7% from 3Q 2022). Net loss: US$115.6m (loss widened US$105.8m from 3Q 2022). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 42% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Nov 02
Cresco Labs Inc. to Report Q3, 2023 Results on Nov 15, 2023 Cresco Labs Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 15, 2023 Tillkännagivande • Oct 20
Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc. Cresco Labs Inc. entered into a definitive agreement to acquire Sole Licensed Arizona Operation of Cresco Labs Inc. for $6.5 million on September 13, 2023. The transaction was closed following approval by the Arizona Department of Health Services. SSC Advisors acted as financial advisor to Cresco Labs
Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc. on October 17, 2023. Breakeven Date Change • Sep 25
No longer forecast to breakeven The 14 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$52.0m in 2025. New consensus forecast suggests the company will make a loss of US$4.17m in 2025. New Risk • Sep 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (24% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$18m net loss in 2 years). Shareholders have been diluted in the past year (8.0% increase in shares outstanding). Recent Insider Transactions • Aug 20
Chief Financial Officer recently bought €101k worth of stock On the 17th of August, Dennis Olis bought around 100k shares on-market at roughly €1.01 per share. This transaction increased Dennis' direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Dennis' only on-market trade for the last 12 months. Tillkännagivande • Aug 17
Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023 Cresco Labs Inc. provided revenue guidance for the second half of 2023. For the period, the company expects total revenue to be down high single digits compared to the first half of the year. Reported Earnings • Aug 17
Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.046 loss in 2Q 2022) Second quarter 2023 results: US$0.14 loss per share (further deteriorated from US$0.046 loss in 2Q 2022). Revenue: US$197.9m (down 7.2% from 2Q 2022). Net loss: US$43.5m (loss widened 221% from 2Q 2022). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Aug 03
Cresco Labs Inc. to Report Q2, 2023 Results on Aug 16, 2023 Cresco Labs Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 16, 2023 Board Change • Aug 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. Independent Director Tarik Brooks was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 25
First quarter 2023 earnings released: US$0.092 loss per share (vs US$0.094 loss in 1Q 2022) First quarter 2023 results: US$0.092 loss per share. Revenue: US$194.2m (down 7.3% from 1Q 2022). Net loss: US$27.8m (loss widened 1.6% from 1Q 2022). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Tillkännagivande • May 13
Cresco Labs Inc. to Report Q1, 2023 Results on May 24, 2023 Cresco Labs Inc. announced that they will report Q1, 2023 results Pre-Market on May 24, 2023 Buying Opportunity • May 11
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 11%. The fair value is estimated to be €1.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 25%. Revenue is forecast to grow by 12% in 2 years. Earnings is forecast to grow by 96% in the next 2 years. Breakeven Date Change • Apr 21
Forecast breakeven date moved forward to 2024 The 13 analysts covering Cresco Labs previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 70% to 2023. The company is expected to make a profit of US$12.8m in 2024. Average annual earnings growth of 120% is required to achieve expected profit on schedule. Buying Opportunity • Apr 18
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 28%. The fair value is estimated to be €1.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has declined by 25%. Revenue is forecast to grow by 0.7% in a year. Earnings is forecast to grow by 78% in the next year. Recent Insider Transactions • Apr 03
Insider recently sold €105k worth of stock On the 29th of March, Dominic Sergi sold around 100k shares on-market at roughly €1.05 per share. This transaction amounted to 26% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €106k. Insiders have been net sellers, collectively disposing of €11m more than they bought in the last 12 months. Recent Insider Transactions • Mar 29
Insider recently sold €106k worth of stock On the 23rd of March, Dominic Sergi sold around 100k shares on-market at roughly €1.06 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €11m more than they bought in the last 12 months. Reported Earnings • Mar 17
Full year 2022 earnings released: US$0.71 loss per share (vs US$1.22 loss in FY 2021) Full year 2022 results: US$0.71 loss per share (improved from US$1.22 loss in FY 2021). Revenue: US$842.7m (up 4.6% from FY 2021). Net loss: US$215.1m (loss narrowed 33% from FY 2021). Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • Dec 04
Co-Founder & Independent Director recently sold €1.2m worth of stock On the 1st of December, Robert Sampson sold around 383k shares on-market at roughly €3.15 per share. This transaction amounted to 62% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Robert's only on-market trade for the last 12 months. Breakeven Date Change • Dec 03
Forecast breakeven date moved forward to 2023 The 19 analysts covering Cresco Labs previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 86% to 2022. The company is expected to make a profit of US$3.08m in 2023. Average annual earnings growth of 93% is required to achieve expected profit on schedule. Breakeven Date Change • Nov 22
Forecast breakeven date pushed back to 2024 The 16 analysts covering Cresco Labs previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 95% per year to 2023. The company is expected to make a profit of US$60.8m in 2024. Average annual earnings growth of 93% is required to achieve expected profit on schedule. Reported Earnings • Nov 16
Third quarter 2022 earnings released: US$0.011 loss per share (vs US$1.00 loss in 3Q 2021) Third quarter 2022 results: US$0.011 loss per share (improved from US$1.00 loss in 3Q 2021). Revenue: US$210.5m (down 1.1% from 3Q 2021). Net loss: US$3.25m (loss narrowed 99% from 3Q 2021). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Breakeven Date Change • Oct 25
No longer forecast to breakeven The 18 analysts covering Cresco Labs no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$19.0m in 2023. New consensus forecast suggests the company will make a loss of US$11.1m in 2024. Reported Earnings • Aug 19
Second quarter 2022 earnings released: US$0.028 loss per share (vs US$0.019 loss in 2Q 2021) Second quarter 2022 results: US$0.028 loss per share (down from US$0.019 loss in 2Q 2021). Revenue: US$218.2m (up 6.2% from 2Q 2021). Net loss: US$8.30m (loss widened 72% from 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Board Change • Aug 19
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Tarik Brooks was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Jul 20
Forecast breakeven date moved forward to 2022 The 16 analysts covering Cresco Labs previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$1.62m in 2022. Earnings growth of 64% is required to achieve expected profit on schedule. Recent Insider Transactions • May 27
Chief Financial Officer recently bought €75k worth of stock On the 24th of May, Dennis Olis bought around 24k shares on-market at roughly €3.12 per share. This was the largest purchase by an insider in the last 3 months. This was Dennis' only on-market trade for the last 12 months. Breakeven Date Change • May 19
Forecast breakeven date pushed back to 2023 The 16 analysts covering Cresco Labs previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 97% to 2022. The company is expected to make a profit of US$100.4m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Reported Earnings • May 19
First quarter 2022 earnings released: US$0.081 loss per share (vs US$0.12 loss in 1Q 2021) First quarter 2022 results: US$0.081 loss per share (up from US$0.12 loss in 1Q 2021). Revenue: US$214.4m (up 23% from 1Q 2021). Net loss: US$23.7m (loss narrowed 20% from 1Q 2021). Over the next year, revenue is forecast to grow 15%, compared to a 6.6% growth forecast for the industry in Germany. Breakeven Date Change • May 11
Forecast breakeven date moved forward to 2022 The 17 analysts covering Cresco Labs previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$34.9m in 2022. Earnings growth of 82% is required to achieve expected profit on schedule. Tillkännagivande • May 07
Cresco Labs Inc. to Report Q1, 2022 Results on May 18, 2022 Cresco Labs Inc. announced that they will report Q1, 2022 results Pre-Market on May 18, 2022 Board Change • Apr 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Tarik Brooks was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Apr 24
Cresco Labs Inc., Annual General Meeting, Jun 30, 2022 Cresco Labs Inc., Annual General Meeting, Jun 30, 2022. Tillkännagivande • Apr 14
Cresco Labs Inc. Launches Floracal Farms Brand to Illinois Cresco Labs announced the launch of its premium craft brand FloraCal Farms, which features unique genetics in curated flower, live rosin vape and live rosin concentrate formats now available at all Illinois Sunnyside stores and other retailers ahead of the 420 cannabis holiday. Born in Sonoma County, FloraCal Farms continues to honor its California heritage through a commitment to tailored craftsmanship established by wife-and-husband founders Karen and Drew Duval, who oversee commercial sales and cultivation at the Company. FloraCal Farms maintains a rigorous pheno-hunting process that starts with hundreds of plants, then hand-selects only the winning strains to be developed into flower, vapes and hand-crafted concentrates. Flower is always hand-harvested, trimmed and packaged to preserve delicate flower characteristics. Live rosin vapes and concentrates follow solventless extraction processes, an innovative method new to Cresco Labs’ wholesale portfolio that removes the oil containing components from the raw materials simply through ice water and manual agitation – without the use of chemical solvents. The resulting materials are pressed to produce live rosin bursting with the terpenes, flavor and potency that cannabis connoisseurs enjoy. Available for sale forms at launch in Illinois include hand-trimmed flower (3.5g), live rosin vape cartridges (500mg) and live rosin badder concentrates (1g). More products and exclusive strains will arrive on dispensary shelves throughout the year. The launch of FloraCal Farms in Illinois rounds out the Company’s wholesale portfolio in Illinois. Other available brands include Cresco, High Supply, Good News, Mindy’s, Wonder Wellness and Remedi. Buying Opportunity • Mar 04
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 26%. The fair value is estimated to be US$7.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 89% per annum over the last 3 years. The company became loss making over the last 3 years. Tillkännagivande • Jan 30
Cresco Labs Announces Launch of Khalifa Kush Products at Cookies Dispensaries Throughout California Cresco Labs announced flower and pre-rolls from Khalifa Kush are available for sale at Cookies stores throughout California. Cresco Labs has an exclusive cultivation and product collaboration agreement with multi-platinum-selling, GRAMMY® and Golden Globe® Award-nominated recording artist Wiz Khalifa’s cannabis brand. Through the partnership, the Company’s FloraCal Farms and Continuum distribution platform will be the sole producer and distributor, respectively, of premium branded products featuring Khalifa Kush’s signature “KK” strain in California. An expanded line is expected to arrive at additional retail partners throughout the year. Tillkännagivande • Dec 12
Cresco Labs Inc. (CNSX:CL) completed the acquisition of Laurel Harvest Labs, LLC for $80 million. Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Laurel Harvest Labs, LLC for $80 million on October 14, 2021. The transaction will include a newly constructed indoor cultivation facility in Lancaster County allowing for new cultivation capacity, the foundation to expand the facility further, and another strategic point of distribution that is complementary to Cresco Labs’ cultivation facility in Brookville. As part of the acquisition, Cresco Labs will also acquire the real estate of Laurel Harvest’s cultivation facility and Scranton dispensary. The purchase price would be payable upon closing of the transaction, subject to the adjustments and lock-up agreements contained in the definitive agreements. Purchase price comprised of a mix of cash and stock, plus earnout amounts payable upon achievement of certain post-closing milestones. The transaction will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The transaction is subject to, among other things, the approval and receipt of all required CSE, regulatory and court approvals. The transaction is expected to close in Q4 of 2021.
Cresco Labs Inc. (CNSX:CL) completed the acquisition of Laurel Harvest Labs, LLC for $80 million on December 10, 2021. John Jones, Joan C. Arnold, Agustin E. Rodriguez, Mamta K. Shah, Julia E. Tomec, Joseph Walsh, Kimberly Hughes Gillespie, and John J. McGrath III from Troutman Pepper Hamilton Sanders LLP acted as a legal advisor to Laurel Harvest Labs. Tillkännagivande • Nov 27
Cresco Labs Inc. (CNSX:CL) completed the acquisition of Bay, LLC. Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Bay, LLC for $90 million on September 23, 2021. The consideration will be satisfied at closing through the payment of cash and stock. The transaction will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The closing of the transaction is subject to, among other things, the approval and receipt of all required CSE and regulatory approvals. The Transaction is expected to close in Q4 of 2021.
Cresco Labs Inc. (CNSX:CL) completed the acquisition of Bay, LLC on November 25, 2021. Reported Earnings • Nov 12
Third quarter 2021 earnings released: US$0.79 loss per share (vs US$0.035 loss in 3Q 2020) The company reported a mediocre third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$215.5m (up 45% from 3Q 2020). Net loss: US$263.5m (loss widened US$256.0m from 3Q 2020). Tillkännagivande • Sep 24
Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Bay, LLC for $90 million. Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Bay, LLC for $90 million on September 23, 2021. The consideration will be satisfied at closing through the payment of cash and stock. The transaction will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The closing of the transaction is subject to, among other things, the approval and receipt of all required CSE and regulatory approvals. The Transaction is expected to close in Q4 of 2021. Breakeven Date Change • Sep 23
Forecast to breakeven in 2022 The 18 analysts covering Cresco Labs expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$129.6m in 2022. Average annual earnings growth of 50% is required to achieve expected profit on schedule. Tillkännagivande • Sep 04
Cresco Labs Inc. (CNSX:CL) completed the acquisition of Cultivate Holdings, LLC. Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Cultivate Holdings, LLC for approximately $160 million on March 18, 2021. Pursuant to the transaction, the agreement will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The consideration details includes $15 million in cash and shares of Cresco having an aggregate value equal to $75 million based on the volume-weighted average closing price of Cresco shares reported on the Canadian Securities Exchange for the ten consecutive trading day period ending on the trading day immediately preceding the date of execution of the definitive agreement. The remaining purchase price shall be structured as an earnout based to the achievement of certain EBITDA target thresholds in 2021, up to $68 million. An amount equal to 12.5% of any earnout payments earned by seller shall be paid in cash. The remaining portion of any earned earnout payments shall be satisfied via issuance of Cresco shares. Approximately 68% of the Cresco shares to be issued to seller upon the closing of the transaction or upon achievement of the earnout, if any, will be subject to the following lock-up restrictions: such Cresco shares shall be released in three equal installments beginning with 1/3rd of the Cresco shares released on each of the following dates: (i) four months following the closing date or the end of the earnout period, as applicable (ii) eight months following the closing date or the end of the earnout period, as applicable; and (iii) twelve months following the closing date or the end of the earnout period, as applicable. The transaction is subject to approval and receipt of all required CSE, regulatory and court approvals, including clearance under Hart-Scott-Rodino Antitrust Improvements Act. As of May 3, 2021, Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in respect to Cresco Labs’ pending acquisition of Cultivate Licensing LLC and BL Real Estate LLC got expired. The Transaction remains subject to certain closing conditions, including approval from the Commonwealth of Massachusetts which is anticipated to be received in the fourth quarter of 2021. The transaction is expected to close in the fourth quarter of 2021. Erica Rice, Jesse Harlan Alderman, Christopher "Kip" Cawley, Teresa A. Martland, Jonathan A. Keselenko, Joshua S. Jarvis, Stacie S. Aarestad and Ryan M. Rourke Reed of Foley Hoag LLP acted as legal advisor to Cultivate Holdings.
Cresco Labs Inc. (CNSX:CL) completed the acquisition of Cultivate Holdings, LLC on September 3, 2021. Director Overboarding • Sep 02
Director Marc Lustig has joined 5th company board Marc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 02
Director Marc Lustig has joined 5th company board Marc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 02
Director Marc Lustig has joined 5th company board Marc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Sep 02
Director Marc Lustig has joined 5th company board Marc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Breakeven Date Change • Aug 18
Forecast breakeven pushed back to 2022 The 16 analysts covering Cresco Labs previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 99% to 2021. The company is expected to make a profit of US$131.8m in 2022. Average annual earnings growth of 50% is required to achieve expected profit on schedule. Tillkännagivande • Aug 18
Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Blair Wellness, LLC. Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Blair Wellness, LLC on August 17, 2021. The consideration will be satisfied through the payment of cash and a twenty-four (24) month promissory note. The Transaction will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The cash consideration would be payable upon closing of the Transaction. The Transaction implies a 1.8x 2021 revenue multiple. Blair Wellness team will join Cresco Family. The closing of the Transaction is subject to, among other things, the approval and receipt of all required CSE and regulatory approvals. The Transaction is expected to close in Q4 of 2021. Acquisition is expected to be immediately accretive. Reported Earnings • Aug 14
Second quarter 2021 earnings released The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$210.0m (up 129% from 2Q 2020). Net loss: US$4.83m (loss narrowed 75% from 2Q 2020). Board Change • Aug 04
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Independent Director Sidney Dillard was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Aug 04
Insider recently sold €3.6m worth of stock On the 26th of July, Dominic Sergi sold around 425k shares on-market at roughly €8.42 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €20m more than they bought in the last 12 months. Tillkännagivande • May 28
Cresco Labs Inc. Provides Earnings Guidance for the Year 2021 Cresco Labs Inc. provided earnings guidance for the year 2021. For the year, the company expects annualized revenue run-rate of more than $1 billion by the end of 2021. Reported Earnings • Mar 27
Full year 2020 earnings released: US$0.17 loss per share (vs US$0.36 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$476.3m (up 284% from FY 2019). Net loss: US$36.6m (loss narrowed 15% from FY 2019). Tillkännagivande • Mar 20
Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Cultivate Holdings, LLC for $158 million. Cresco Labs Inc. (CNSX:CL) entered into a definitive agreement to acquire Cultivate Holdings, LLC for $158 million on March 18, 2021. Pursuant to the transaction, the agreement will be completed on a cash-free, debt-free basis with a mutually agreed upon normalized target level of working capital. The consideration details includes $15 million in cash and shares of Cresco having an aggregate value equal to $75 million based on the volume-weighted average closing price of Cresco shares reported on the Canadian Securities Exchange for the ten consecutive trading day period ending on the trading day immediately preceding the date of execution of the definitive agreement. The remaining purchase price shall be structured as an earnout based to the achievement of certain EBITDA target thresholds in 2021, up to $68 million. An amount equal to 12.5% of any earnout payments earned by seller shall be paid in cash. The remaining portion of any earned earnout payments shall be satisfied via issuance of Cresco shares. Approximately 68% of the Cresco shares to be issued to seller upon the closing of the transaction or upon achievement of the earnout, if any, will be subject to the following lock-up restrictions: such Cresco shares shall be released in three equal installments beginning with 1/3rd of the Cresco shares released on each of the following dates: (i) four months following the closing date or the end of the earnout period, as applicable (ii) eight months following the closing date or the end of the earnout period, as applicable; and (iii) twelve months following the closing date or the end of the earnout period, as applicable. The transaction is subject to approval and receipt of all required CSE, regulatory and court approvals, including clearance under Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close in the fourth quarter of 2021. Tillkännagivande • Mar 05
Cresco Labs Inc. to Report Q4, 2020 Results on Mar 25, 2021 Cresco Labs Inc. announced that they will report Q4, 2020 results Pre-Market on Mar 25, 2021 Tillkännagivande • Feb 18
Cresco Labs Inc. (CNSX:CL) acquired Four dispensaries of Verdant Creations. Cresco Labs Inc. (CNSX:CL) acquired Four dispensaries of Verdant Creations on February 16, 2021. These acquisitions give Cresco Labs Inc. four additional dispensaries, bringing Cresco Labs Inc. dispensary presence in Ohio to five.
Cresco Labs Inc. (CNSX:CL) completed the acquisition of Four dispensaries of Verdant Creations on February 16, 2021. Tillkännagivande • Feb 10
Cresco Labs Signs Exclusive Distribution Agreement with California Cannabis Producer, Emerald Family Farms Cresco Labs announced that it has entered into an exclusive distribution agreement with Emerald Family Farms. The Agreement will bring EFF’s award-winning lineup of jarred flower, pre-rolls and concentrates onto Cresco’s California distribution platform. This Agreement continues to build on that strength with some of the best flower in California being added to company roster of top performing California brands. Having brought hundreds of the region’s finest farmers under one banner, EFF’s success story is proof that exceptional cannabis and uncompromising values can coexist. 
